New drug combo aims to keep bladder cancer at bay after chemo
NCT ID NCT04678362
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing whether a combination of two drugs, Talazoparib and Avelumab, can help keep advanced urothelial (bladder) cancer from growing after initial chemotherapy. About 50 adults with platinum-sensitive cancer will receive the drugs as maintenance therapy until the cancer progresses or side effects become too much. The main goal is to see how long patients live without their cancer worsening.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Talazoparib and Avelumab
What this could lead to
If successful, this combination could offer a new maintenance option to delay cancer progression after initial chemotherapy.
What could go wrong
This is a small, early-phase trial (50 patients) with no control group, so results may not be definitive. Side effects from the drugs could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Jean Minjoz
RECRUITINGBesançon, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Centre Antoine Lacassagne
RECRUITINGNice, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Centre Eugène Marquis
RECRUITINGRennes, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Centre François baclesse
ACTIVE_NOT_RECRUITINGCaen, 14000, France
-
Centre George-François Leclerc
RECRUITINGDijon, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Centre Jean Perrin
RECRUITINGClermont-Ferrand, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Centre Léon Bérard
RECRUITINGLyon, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Croix Saint-Simon Diaconesses
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hopital Tenon
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospices civils de Lyon
ACTIVE_NOT_RECRUITINGLyon, France
-
IUCT
RECRUITINGToulouse, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Institut Paoli Calmettes
NOT_YET_RECRUITINGMarseille, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Institut de Cancérologie de l'Ouest
RECRUITINGAngers, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Institut de Cancérologie de l'Ouest
RECRUITINGNantes, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact